Association of maternal and umbilical cord blood asprosin with excessive gestational weight gain.

Maternal obesity and excessive gestational weight gain (EGWG) may have persistent effects on offspring obesity and be risk factors for both mother and child. Studies have reported that asprosin concentration is associated with metabolism and weight changes during pregnancy. This study therefore evaluated the association of maternal and newborn asprosin with normal weight gain and EGWG and nutritional intake in pregnancy. The study included 30 pregnant women with normal weight gain and 30 women with EGWG referred to Ali ibn Abi Talib Hospital in Zahedan, Iran, September 2020 to June 2021. A demographic questionnaire and neonatal complications checklist were completed. Asprosin concentrations at the time of delivery in maternal venous blood samples and umbilical vein blood samples were measured by ELISA technique. Macronutrient and energy intake were assessed by a 24-h dietary recall questionnaire and compared with standard Recommended Dietary Allowance (RDA) and Dietary References Intake (DRI) values. Asprosin levels were significantly higher in the EGWG group's umbilical cord blood than in the control group but there was no difference in maternal asprosin concentrations between the two groups. The Appearance, Pulse, Grimace, Activity and Respiration (Apgar) score was significantly lower in the EGWG group than in the control group, although there was no difference in birthweight between the groups. Weight gain during pregnancy, energy intake and protein and carbohydrate consumption were significantly higher in the EGWG group than in the control group (p < 0.05). It seems that differences in asprosin secretion do not mediate an imbalance in energy intake and other macronutrients during pregnancy that affect pregnancy weight gain and birthweight. However, excessive gestational weight gain was associated with neonatal asprosin levels and newborn Apgar scores.